The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy. ⋯ Fetal exposure to magnesium sulfate before anticipated early preterm delivery did not reduce the combined risk of moderate or severe cerebral palsy or death, although the rate of cerebral palsy was reduced among survivors. (ClinicalTrials.gov number, NCT00014989.)
-
Randomized Controlled Trial Multicenter Study Comparative Study
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis. ⋯ Adalimumab therapy seems to be an efficacious option for the treatment of children with juvenile rheumatoid arthritis. (ClinicalTrials.gov number, NCT00048542.)
-
Randomized Controlled Trial Multicenter Study
Effect of PCI on quality of life in patients with stable coronary disease.
It has not been clearly established whether percutaneous coronary intervention (PCI) can provide an incremental benefit in quality of life over that provided by optimal medical therapy among patients with chronic coronary artery disease. ⋯ Among patients with stable angina, both those treated with PCI and those treated with optimal medical therapy alone had marked improvements in health status during follow-up. The PCI group had small, but significant, incremental benefits that disappeared by 36 months. (ClinicalTrials.gov number, NCT00007657.)
-
Randomized Controlled Trial Multicenter Study Comparative Study
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Whether bivalirudin is superior to unfractionated heparin in patients with stable or unstable angina who undergo percutaneous coronary intervention (PCI) after pretreatment with clopidogrel is unknown. ⋯ In patients with stable and unstable angina who underwent PCI after pretreatment with clopidogrel, bivalirudin did not provide a net clinical benefit (i.e., it did not reduce the incidence of the composite end point of death, myocardial infarction, urgent target-vessel revascularization, or major bleeding) as compared with unfractionated heparin, but it did significantly reduce the incidence of major bleeding. (ClinicalTrials.gov number, NCT00262054.)